Lapatinib and Bevacizumab for Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Neoplasms, Breast

In brief

This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.

Key facts

Study ID

NCT00444535

Run by

Novartis Pharmaceuticals

People needed

52

Starts

2007-02-27

Expected to finish

2020-06-19

Last updated by the study team

2021-10-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females that are at least 18 years of age.
• Women of childbearing potential must have a negative serum pregnancy test at screening.
• Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting.
• Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic.
• Adequate hepatic, renal and cardiac function
• ECOG score 0-1 and a life expectancy of at least 12 weeks.
• Able to swallow oral medication
• Signed informed consent

You may not qualify if…

• Pregnancy
• Unstable or symptomatic CNS metastases
• Major surgery within 28 days of enrollment (minor surgery within 7 days).
• Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities.
• A serious non-healing wound, ulcer, or bone fracture at baseline.
• Class II, III or IV heart failure as defined by the NYHA functional classification system
• History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension.
• History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment.
• History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment.
• History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.
• Proteinuria
• Requires concurrent anti-cancer treatment or investigational treatment.
• Known hypersensitivity to either study medication
• Received investigational treatment within 28 days or 5 half-lives, whichever is longer
• Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study
• Requires medication that has been excluded during study participation

Where it is running

• Novartis Investigative Site — Tucson, Arizona, United States
• Novartis Investigative Site — San Francisco, California, United States
• Novartis Investigative Site — Hollywood, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigative Site — Basking Ridge, New York, United States
• Novartis Investigative Site — Commack, New York, United States
• Novartis Investigative Site — New York, New York, United States
• Novartis Investigative Site — Rockville Centre, New York, United States
• Novartis Investigative Site — Sleepy Hollow, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.